Literature DB >> 11862498

Delayed emesis: incidence, pattern, prognostic factors and optimal treatment.

Fausto Roila1, Donatella Donati, Stefano Tamberi, Guido Margutti.   

Abstract

Delayed emesis has been arbitrarily defined as vomiting and/or nausea beginning, or persisting for, more than 24 h after chemotherapy administration. Acute emesis is the most important prognostic factor for delayed emesis. Owing to the relatively high incidence and severity all patients treated with cisplatin > or = 50 mg/m(2) should receive antiemetic prophylaxis. In these patients a combination of dexamethasone plus metoclopramide or a 5-HT3 antagonist is the most efficacious regimen. All patients submitted to moderately emetogenic chemotherapy, such as cyclophosphamide, carboplatin, doxorubicin and epirubicin, should also receive antiemetic prophylaxis with oral dexamethasone to prevent delayed emesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11862498     DOI: 10.1007/s005200100295

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  18 in total

1.  Nausea and emesis: still an unsolved problem in cancer patients?

Authors:  Jørn Herrstedt
Journal:  Support Care Cancer       Date:  2002-01-31       Impact factor: 3.603

2.  The impact of chemotherapy-induced nausea and vomiting on health-related quality of life.

Authors:  Enzo Ballatori; Fausto Roila; Benedetta Ruggeri; Maura Betti; Samanta Sarti; Giancarla Soru; Giorgio Cruciani; Massimo Di Maio; Biffi Andrea; Robert R Deuson
Journal:  Support Care Cancer       Date:  2006-08-29       Impact factor: 3.603

3.  Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.

Authors:  Ronald Chow; David G Warr; Rudolph M Navari; May Tsao; Marko Popovic; Leonard Chiu; Milica Milakovic; Henry Lam; Carlo DeAngelis
Journal:  Support Care Cancer       Date:  2018-05-23       Impact factor: 3.603

4.  Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).

Authors:  Paul J Hesketh; David G Warr; James C Street; Alexandra D Carides
Journal:  Support Care Cancer       Date:  2010-07-11       Impact factor: 3.603

5.  Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting.

Authors:  Thaiana Aragão Santana; Damila Cristina Trufelli; Leandro Luongo de Matos; Felipe Melo Cruz; Auro Del Giglio
Journal:  Support Care Cancer       Date:  2014-08-22       Impact factor: 3.603

6.  Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study.

Authors:  Carlo Pirri; Paul Katris; James Trotter; Evan Bayliss; Robert Bennett; Peter Drummond
Journal:  Support Care Cancer       Date:  2010-09-03       Impact factor: 3.603

7.  Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance).

Authors:  Debra L Barton; Gita Thanarajasingam; Jeff A Sloan; Brent Diekmann; Jyotsna Fuloria; Lisa A Kottschade; Alan P Lyss; Anthony J Jaslowski; Miroslaw A Mazurczak; Scott C Blair; Shelby Terstriep; Charles L Loprinzi
Journal:  Cancer       Date:  2014-07-09       Impact factor: 6.860

8.  A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design.

Authors:  P C Nathan; G Tomlinson; L L Dupuis; M L Greenberg; S Ota; U Bartels; B M Feldman
Journal:  Support Care Cancer       Date:  2005-07-29       Impact factor: 3.603

9.  Chemotherapy-induced nausea and vomiting in routine practice: a European perspective.

Authors:  Agnes Glaus; Cornelia Knipping; Rudolf Morant; Christel Böhme; Burkhard Lebert; Frank Beldermann; Bernhard Glawogger; Paz Fernandez Ortega; André Hüsler; Robert Deuson
Journal:  Support Care Cancer       Date:  2004-10       Impact factor: 3.603

10.  A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre.

Authors:  A Molassiotis; M P Saunders; J Valle; G Wilson; P Lorigan; A Wardley; E Levine; R Cowan; J Loncaster; C Rittenberg
Journal:  Support Care Cancer       Date:  2007-10-10       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.